Warner-Lambert's Eryc
Executive Summary
Oral antibiotic has captured 28% of $130 mil. U.S. erythromycin market to become the market leader with approximately $36 mil. in U.S. sales, according to F. H. Faulding, the Australian firm that licenses the drug to Parke-Davis. Faulding also reports that sales of oral doxycycline Doryx have reached $5.5 mil. in the U.S. since the product was launched in February. Doryx is also licensed to Warner-Lambert.